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ABSTRACT
Background: Skeletal muscle loss, commonly known as sarcopenia, is highly 
prevalent in older adults and linked with adverse outcomes in cancer, yet the definition 
and role of sarcopenia remains uncertain. The aim of this study was to examine the 
association of Computerized Tomography (CT) assessed skeletal muscle measures 
with physical function in older adults with cancer.
Results: CTs for 185 patients were available. Median age 73 (IQR 68–76) and 
56.5% female. After controlling for sex and BMI, we found no evidence that SMI was 
associated with physical function impairments. Both SMD and SMG were associated 
physical function impairments and higher values were associated with decreased 
limitations in instrumental activities of daily living (RR 0.84 [CI 0.73–0.96] and 
0.94 [CI 0.89–0.99], respectively), climbing stairs (RR 0.84 [CI 0.76–0.94] and 0.91 
[CI 0.87–0.96]), walking 1 block (RR 0.77 [CI 0.67–0.90] and 0.91 [CI 0.85–0.97]), 
and prolonged Timed Up and Go (RR 0.83 [CI 0.75–0.92] and 0.92 [CI 0.88–0.96]).
Materials and Methods: Using the Carolina Senior Registry, we identified patients 
with CT imaging performed within 60 days +/− of baseline geriatric assessment (GA). 
Skeletal muscle area and density (SMD) were analyzed from L3 lumbar segments. 
Muscle area and height (m2) were used to calculate skeletal muscle index (SMI). 
Skeletal Muscle Gauge (SMG) was created by multiplying SMI x SMD. 
Conclusions: Skeletal muscle mass as assessed from CT imaging was not 
associated with physical function impairments. Skeletal muscle radiodensity was 
more associated with physical function and may aid in identifying older adults at risk 
for functional impairments.
INTRODUCTION
Skeletal muscle depletion, commonly known as 
sarcopenia within oncology, is highly prevalent in older 
adults with cancer and has been linked to increased 
toxicity and mortality in a variety of cancer types 
[1, 2]. Body composition analysis is not yet a standard 
part of the assessment of adults with cancer; however, 
computerized tomography (CT) images obtained as part of 
routine cancer staging and disease assessment are readily 
available tools that represent a nascent opportunity to 
provide additional prognostic information, particularly in 
older adults. Consistent methods for utilizing CT imaging 
to achieve practical and precise measurements of body 
composition exist and can be performed clinically without 
significant resource allocation [3]. These methods allow 
for practical CT-based measurements of skeletal muscle 
mass and radiodensity, as well as subcutaneous and 
visceral adiposity.
The precise definition of sarcopenia remains 
controversial. The term sarcopenia was first popularized 
in a study by Baumgartner et al. to describe age-related 
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muscle mass loss seen in older adults in New Mexico [4]. 
Using dual-energy X-ray absorptiometry (DEXA), 
sarcopenia was defined as two standard deviations below 
the mean muscle mass of healthy younger adults and 
was shown to be highly prevalent in older adults. Ever 
since the term sarcopenia was introduced, numerous 
definitions have subsequently been used in the literature. 
A recent meta-analysis examining the prognostic value of 
sarcopenia in adults with solid tumors found 11 different 
definitions of sarcopenia in the included 38 studies [1]. 
The prevalence of sarcopenia using these various cut-
points was wide ranging, from 11–74% depending on the 
study population and definition employed. These various 
definitions used in oncology based solely on low skeletal 
muscle mass, typically derived from optimum stratification 
analyses based on increased mortality or other adverse 
outcomes, limit the generalizability of studies and our 
understanding of study results.
Due to these challenges, a Sarcopenia Working 
Group was formed in 2009 to develop operational 
definitions and diagnostic criteria of sarcopenia, and 
ultimately recommended using both the presence of low 
muscle mass as well as evidence of low muscle strength or 
physical performance for the diagnosis of sarcopenia [5]. 
This two-part criterion for defining sarcopenia was 
suggested because the relationship between muscle 
strength and mass is not linear and muscle strength 
does not depend solely on muscle mass [6, 7]. Other 
important factors, such as muscle composition and fatty 
infiltration of muscle, complicate the use of muscle mass 
alone in defining sarcopenia. The working group also 
developed conceptual stages of sarcopenia that include 
pre-sarcopenia (low muscle mass alone), sarcopenia 
(low muscle mass with either reduced muscle strength or 
impaired physical performance), and severe sarcopenia 
(low muscle mass, reduced muscle strength, and impaired 
physical performance) [5]. Additional proposed clinical 
criteria for diagnosing sarcopenia developed since that 
time also highlight the importance of muscle weakness 
and poor physical function, and explicitly recommend 
against the use of reduced muscle mass alone [8, 9]. 
Furthermore, other terms such as myopenia and muscle 
wasting diseases have been developed and are suggested 
for use when describing clinically relevant muscle wasting 
that is not associated with loss of muscle strength or poor 
physical performance [10, 11].
Despite these guidelines, studies across the oncology 
field only utilize CT-based definitions of sarcopenia and 
often lack collaborative information on muscle strength 
or physical function. Therefore, we sought to explore 
the association of single-slice CT-based skeletal muscle 
measurements with physical function in older adults (age 
≥ 65) with cancer. We hypothesized that skeletal muscle 
mass as measured by single-slice CT-imaging would 
be associated with physical performance and physical 
impairments.
RESULTS
Study population
For the 185 patients included in this study, mean 
age was 73 (standard deviation 6.8 years), 57% female, 
and 84% Caucasian (See Table 1). Most common cancer 
types included breast cancer (30%), lung cancer (20%), 
gastrointestinal malignancies (14%), and genitourinary 
malignancies (11%). The median time between the 
receipt of CT imaging and GA performance was 2 days 
(interquartile range of −16 to 0), and 83% of patients 
had imaging and the GA performed within 30 days of 
each other. Thirty-one percent of patients had the GA 
performed before cancer treatment was initiated and 51% 
during treatment. Forty-two percent of the sample had an 
impairment in IADL, 25% with one or more falls, and 
44% with a prolonged TUG.
Body composition metrics
Patients exhibited a wide variation in body 
composition. The average BMI was 27.1 (range 15.4–51.6), 
SMI 41.8 cm2/m2 (range 23–67), SMD 26.2 HU (range 
3.9–47), and SMG 1103 AU (range 89–2760). Significant 
differences in SMI and SMG were found between men 
and women (45.7 versus 38.8 cm2/m2, p < 0.001 and 1244 
versus 1000 AU, p < 0.001, respectively), while there was 
no differences in SMD or BMI by sex.
Physical function and body composition 
correlations
No significant association of SMI with any measure 
of impaired physical function was found (See Table 2). 
Significant decreases in risk of impairment were found for 
increasing levels of both SMD and SMG with prolonged 
TUG, impaired IADL, climbing 1 flight of stairs, 
walking 1 block, and bending, kneeling, or stooping. For 
example, for each 5 unit increase in SMD, a patient’s risk 
of having a prolonged TUG decreased by 17%. For each 
100 unit increase in SMG, the risk of prolonged TUG 
decreased by 8%. Increasing SMD, but not SMG, was also 
found to be associated with lower risk of limitations in 
moderate activities. There was no significant association 
with low KPS, the presence of falls, or impaired bathing/
dressing with any skeletal muscle metric. Even after 
additionally controlling for age and BMI in a secondary 
model, SMD and SMG remained significantly associated 
with physical function impairments, with the exception of 
the loss of significance with IADL for both. The model fit 
was similar for both models (with and without controlling 
for age and BMI), and overall AUCs ranged from 0.6 to 
0.7. Furthermore, no differences in RR were found after 
controlling for treatment stage. Using the most commonly 
employed cut-point of SMI to define sarcopenia [12], we 
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Table 1: Patient characteristics
Total Sample (n = 185)
Age, mean (range, SD) 73 (65–93, 6.8)
Gender, n (%)
 Male
 Females
80 (43)
105 (57)
Race, n (%)
 Caucasian
 Black
 Other
155 (84)
28 (15)
2 (1)
Cancer type, n (%)
 Breast cancer
 Lung cancer
 GI Malignancy
 GU Malignancy
 Heme Malignancy
 Other
53 (30)
35 (20)
25 (14)
20 (11)
16 (9)
30 (17)
Treatment Phase, n (%)
 Before Treatment
 During Treatment
 After Treatment
56 (31)
90 (51)
33 (18)
Education, n (%)
 Some high school
 High school degree
 Associates/Bachelor’s degree
 Advanced degree
24 (15)
75 (46)
35 (21)
29 (18)
Geriatric Assessment, n (%)
 KPS < 80
 1 or more falls
 Prolonged TUG
 IADL Impairment
 Impaired bathing or dressing
 Limited moderate activities
 Limited climbing 1 flight of stairs
 Limited walking 1 block
 Limited bending, kneeling, or stooping
43 (27)
40 (25)
81 (44)
64 (42)
27 (17)
78 (48)
57 (36)
48 (30)
76 (47)
Abbreviations: GI, gastrointestinal; GU, genitourinary; KPS, Karnofsky Performance Status; TUG, Timed Up and Go; IADL, 
Instrumental Activities of Daily Living.
Table 2: Relative risk of impairments in physical function by skeletal muscle measures after 
controlling for sex (N = 185)
KPS < 80 ≥ 1 falls Prolonged TUG
Impaired 
IADL
Impaired Bathing 
and dressing
Limited Moderate 
activities
Limited in climbing 
1 flight of stairs
Limited in 
walking 1 block
Limited in bending, 
kneeling or stooping
SkeletalMuscle Index† 1.03
(0.87, 1.21)
0.89
(0.74, 1.07)
0.88
(0.77, 1.00)
0.96
(0.84, 1.10)
1.08
(0.86, 1.35)
1.04
(0.94, 1.14)
0.92
(0.80, 1.07)
0.93
(0.79, 1.10)
1.01
(0.91, 1.12)
SkeletalMuscle Density† 0.88(0.76, 1.02)
0.98  
(0.83, 1.15)
0.83*  
(0.75, 0.92)
0.84**
(0.73, 0.96)
0.85
(0.70, 1.03)
0.91*
(0.85, 0.99)
0.84**
(0.76, 0.94)
0.77**
(0.67, 0.90)
0.87**
 (0.79, 0.95)
Skeletal Muscle Gauge†† 0.95
(0.89, 1.01)
0.98
(0.91, 1.05)
0.92**
(0.88, 0.96)
0.94*
(0.89, 0.99)
0.95
(0.87, 1.03)
0.97
(0.94, 1.01)
0.91**
(0.87, 0.96)
0.91**
(0.85, 0.97)
0.95*
(0.91, 0.99)
*p = < 0.05 **p = < 0.01.
†Relative risks for SMI and SMD are for each 5 unit increase and not single units.
††Relative risks for SMG are for each 100 point increase and not single units.
Abbreviations: SMI, Skeletal Muscle Index; SMD, Skeletal Muscle Density; SMG, Skeletal Muscle Gauge; KPS, Karnofsky Performance Status; TUG, Timed Up and Go; IADL, Instrumental Activities of 
Daily Living.
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found no statistically significant differences in physical 
function impairments between sarcopenic and non-
sarcopenic patients (data not shown).
As the TUG is a well validated objective measure 
of physical performance [13], we chose to further explore 
this measure as a continuous variable. We limited this 
analysis to individuals that were able to complete the TUG 
(n = 132) and excluded those that were either unable to 
complete (n = 51) or were missing the score (n = 2). SMI 
had a weak negative correlation with TUG completion 
times (rho = −0.11, slope = −0.24, p = 0.19) (See Figure 1). 
Both SMD and SMG had moderate negative correlations 
with TUG completion times (rho = −0.28, p = 0.001 and 
rho = −0.25, p = 0.001, respectively). We also explored 
imputed the results of participants unable to complete the 
TUG assessment as prolonged (at 30 seconds), and this 
did not substantially alter the correlations. The predicted 
SMI, SMD, and SMG for a TUG time of 14 seconds were 
41.8 cm2m2, 26.1HU, and 1110.5 AU respectively.
DISCUSSION
Low skeletal muscle mass, referred to as sarcopenia 
within oncology, has been associated with adverse 
outcomes including treatment-related toxicity and death 
in patients with cancer. In our sample of older adults with 
cancer undergoing GA, contrary to our original hypothesis 
we found skeletal muscle mass was not associated with 
physical function or impairments in physical function. 
Furthermore, using cut-points commonly reported in the 
oncology literature, we also found no association with 
physical function impairments. Rather, skeletal muscle 
attenuation (represented as SMD), which reflects muscle 
lipid content, was more associated with physical function 
than just muscle quantity. This suggests that focusing 
on SMI alone for a definition of sarcopenia, as most 
publications within oncology have to date, misses critical 
information regarding physical function and performance. 
Commonly used definitions of sarcopenia in oncology 
research based on muscle mass alone poorly correspond to 
the consensus definition of sarcopenia used more broadly 
within the literature [5, 8].
Although contrary to our original hypothesis, our 
results are in line with others outside of the oncology 
field. The Health, Aging and Body Composition (Health 
ABC) study was designed to prospectively determine 
the role of changes in body composition in community 
dwelling older adults and represents one of the largest 
prospective studies to date exploring body composition. 
In their study of 3,075 patients, they showed that muscle 
attenuation and muscle strength were the only measures 
that independently predicted physical function [14]. 
They also found that reduced muscle attenuation was 
independently associated with poor lower extremity 
performance [15]. Although muscle mass does play a role 
in strength and performance, changes in lean mass only 
explain a small portion of variability of strength decline 
(~5%) and attenuation values of muscle on CT appear to 
account for differences in muscle strength not attributed to 
muscle quantity [6, 16]. The Health ABC study ultimately 
concluded that strength, as a marker of muscle quality, 
and not muscle mass (i.e. quantity), was most important 
in estimating mortality [17].
The field of oncology has examined body 
composition and sarcopenia through a different lens. 
Cancer cachexia is a multifactorial syndrome caused 
by a combination of elevated inflammatory response, 
alterations in metabolism, and reduced food intake [18]. 
Cancer associated skeletal muscle wasting is likely 
caused by a multitude of factors, some similar and some 
dissimilar, compared to skeletal muscle loss in non-
cancer populations [18]. There is a clear and consistent 
association of skeletal muscle loss with poorer outcomes 
in cancer; including increased chemotherapy toxicity 
and reduced overall survival [1, 19]. However, a focus 
purely on skeletal muscle quantity omits important 
information and does not appear to tell the whole story. 
Oncologic studies examining skeletal muscle should 
ideally incorporate several metrics of skeletal muscle to 
fully appreciate and assess the complexity of sarcopenia 
and better understand its relationship to important cancer-
specific outcomes. As the term sarcopenia has now been 
defined with its own ICD10 code (M62.84) to include 
both decreased muscle mass and weakness that results in 
functional problems, myopenia or the more general term 
muscle wasting may be a better term to replace sarcopenia 
when focusing solely on clinically relevant muscle loss 
[10, 11]. Myopenia specifically describes clinically 
relevant muscle loss or wasting that is associated with 
increased risk of morbidity or mortality [11].
Our study has several limitations. As our data 
was cross-sectional, we cannot address whether there 
is a causal relationship between physical function and 
fat infiltration in muscle. Whether the presence of fatty 
infiltration of muscle directly affects muscle contractility, 
muscle fiber recruitment, or muscle metabolism, thereby 
affecting muscle function, remains unknown. As our study 
sample included a variety of cancer types across various 
time points in the cancer care continuum, we are not able 
to draw any conclusions regarding the impact of cancer 
and its treatment on skeletal muscle or physical function. 
More specifically, about half of our sample was actively 
receiving oncologic treatment and it is well-known that 
cancer treatments can impact physical function [20]; 
however, it is uncertain how this may have impacted our 
correlations between physical function and CT imaging. 
Our study was meant to be an exploratory cross-sectional 
study across all cancer types, and clearly more work is 
needed to understand the impact of specific cancers and 
treatments on body composition. We measured physical 
function as part of a routine GA and do not have direct 
measures of muscle strength (such as grip strength or 
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knee flexor) that would have provided additional detail. 
Therefore, we reported muscle “quality” only per mean 
muscle density and were not able to calculate strength per 
unit of muscle mass.
In summary, we have shown that skeletal muscle 
mass obtained from routine CT imaging was not 
associated with physical function impairments and was 
poorly correlated with physical performance in our sample 
of older adults with cancer. The ‘quality’ and composition 
of skeletal muscle, rather than the quantity, is likely more 
important in identifying and understanding impairments 
in physical function. Although traditional cutpoints used 
for defining sarcopenia in oncology are associated with 
increased mortality, they are poorly correlated with 
physical function and not consistent with the broader 
definition of sarcopenia. We suggest that studies that focus 
solely on muscle loss or wasting use the term myopenia 
or the more general term “muscle wasting disease” rather 
than sarcopenia [10, 11]. Further prospective work is 
necessary to adequately define and understand sarcopenia 
in adults with cancer that includes skeletal muscle metrics, 
muscle strength, and physical function. Until that time, 
incorporating skeletal muscle attenuation into CT imaging 
based studies as a surrogate of muscle composition may 
be beneficial to better understand physical function and 
performance. Using an integrated measurement of both 
attenuation and mass, such as SMG, may represent a 
promising integration of these two important variables 
that requires further exploration. CT imaging based body 
composition measures represent a unique and potentially 
promising opportunity to identify adults with cancer at risk 
for poor outcomes and may be useful in targeting future 
interventions.
MATERIALS AND METHODS
Participants
The sample for this study was derived from the 
Carolina Seniors Registry (CSR) (NCT01137825). The 
CSR was developed in 2009 as a large observational 
cancer registry to collect geriatric assessment (GA) data 
on older adults (≥ 65) with cancer. The CSR eligibility 
includes any patient age 65 or greater with a diagnosis 
of cancer. The only exclusion criteria includes the ability 
to speak and read English, as the GA questionnaires and 
assessments are not validated in other languages. As the 
CSR is predominately a research tool, the GAs were 
performed by our research staff. For a more detailed 
description of the CSR including the sampling methods, 
recruiting procedures, and performance of assessments, 
please see Williams et al. [21]. Using the CSR and 
electronic medical records, we identified patients recruited 
at the outpatient clinics of the North Carolina Cancer 
Hospital with any available CT abdominal imaging 
within 60 days of completing the GA. Of the 771 patients 
available with the CSR, 207 had abdominal CT imaging 
within 60 days of the completion of GA measures, and 
185 with CT images adequate for body composition 
evaluation. This study was approved by the Institutional 
Review Board of the University of North Carolina (IRB 
#15–1524).
Physical function measures
The CSR utilizes a validated GA tool designed 
specifically for use in older adults with cancer [21, 22]. 
Figure 1: Correlation of skeletal muscle measures and Timed Up and Go (N = 132). Illustrates the correlation of skeletal 
muscle measures with performance on the Timed Up and Go (TUG) physical performance assessment. Skeletal muscle index has a very 
weak negative correlation with TUG scores (−0.11) while skeletal muscle density and skeletal muscle gauge have a moderate negative 
correlation (−0.28 and −0.25, respectively). We limited this analysis to individuals that were able to complete the TUG (n = 132) and 
excluded those that were either unable to complete (n = 51) or were missing the score (n = 2).
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The GA is comprised of both a health-care professional 
portion and patient reported measures. For the purposes of 
this study, we restricted our focus to the physical function 
domain within the GA. The health-care provider assessed 
function through the Timed Up and Go (TUG) test [13] 
and the Karnofsky Performance Status (KPS) scale [23] 
and patient-reported measures of instrumental activities 
of daily living (IADL) [24], self-reported falls [25], and 
physical health [26]. The KPS is a global composite 
measure that assesses the ability to perform normal 
activity and the amount of assistance required. The KPS 
scale generally ranges from 20 (“very sick, hospitalization 
required) to 100 (normal, no complaints) and was rated by 
the research staff at the time of performing the GA [23]. 
The TUG test asks the participant to stand from a chair, 
walk a distance of approximately 10 feet, turn around, 
walk back to their chair, and sit-down. The total seconds 
required to complete the test is recorded or “inability to 
complete” is noted if a participant is unable to complete 
the test. The GA utilizes the physical health questionnaire 
from the Medical Outcomes Survey that inquiries about 
limitations in engaging in various physical activities [26]. 
Cut-points were used to define impairments for each 
respective scale or measure based on the support literature 
as previously published [27]. These include a KPS < 80 
[23], the presence of 1 or more falls [27], a TUG test 
greater than 14 seconds [13], and any reported impairment 
or limitation in IADL or physical health activity [24, 26]. 
CT-based body composition analysis
Abdominal CT images were acquired from the 
UNC Picture Archiving and Communication office. 
Using Impac radiological software (Mountain View, CA), 
transverse sections at the L3 vertebral level were identified 
and extracted for external analysis. Automated image 
segmentation software was then used to analyze the 
L3 lumbar segments [28, 29]. The software recognizes 
muscle tissue based on density thresholds between −29 
and +150 Hounsfield Units (HU) and provides an unbiased 
estimation of the cross-sectional skeletal muscle area. 
Images were then reviewed and corrected for accuracy 
and verified by two authors (GRW, SSS). The measured 
skeletal muscle area was then normalized for height (in 
meters) to calculate a skeletal muscle index (SMI) (cm2/m2) 
using the following formula: (skeletal muscle area-cm2)/ 
(patient height-m2). Skeletal muscle density (SMD) was 
derived by averaging the HU of skeletal muscle of the 
cross-sectional image. The attenuation of skeletal muscle 
is a non-invasive radiological technique to indirectly 
assess muscle fat content, known as myosteatosis. The 
density of skeletal muscle is inversely related to muscle 
fat content [30]. 
To integrate both the quantity (SMI) and attenuation 
(SMD), we generated the skeletal muscle gauge (SMG) 
by multiplying SMI x SMD. The actual units for SMG 
are (cm2 tissue area x average HU)/ (m2 height) and for 
simplicity we chose to represent as arbitrary units (AU). 
This method was first introduced by Weinberg et al. and 
showed better correlation with aging than either SMD 
or SMI alone [31]. SMG has also been associated with 
toxicity and survival in adults with metastatic breast 
cancer receiving taxane therapy [32]. 
Statistical analysis
Descriptive statistics summarize the baseline 
characteristics of the sample, and independent t-tests are 
used to compare differences in skeletal muscle measures 
between the individual physical function variables. 
Given the known significant differences by gender in 
body composition metrics, we controlled for sex in the 
log-binomial regression models. Relative risks based on 
increasing levels of the continuous body composition 
measures are reported, along with 95% confidence 
intervals. Secondary models were fit adjusting for sex, age, 
treatment phase, and BMI, and model fit was evaluated 
by comparing the area under the receiver operating curve 
(AUC). Pearson correlation coefficients are reported for 
the relationship between continuous TUG completion 
scores and skeletal muscle measures, and linear regression 
was used to estimate the slope of the best fit line. SAS 
statistical software version 9.4 (SAS Institute Inc., Cary, 
NC) was used for all analyses.
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